Louis-Philippe Laurin1, Patrick H Nachman1, Payal C Desai2, Kenneth I Ataga3, Vimal K Derebail1. 1. UNC Kidney Center, Division of Nephrology and Hypertension, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 2. Division of Hematology, Department of Medicine, The Ohio State University College of Medicine, Columbus, OH, USA. 3. Division of Hematology and Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Abstract
BACKGROUND: Albuminuria is an early manifestation of sickle cell nephropathy. Prior small case series suggests benefit of hydroxyurea in reducing albuminuria, with a similar trend noted in pediatric studies. We aimed to comprehensively evaluate hydroxyurea use and prevalence of albuminuria in adult sickle cell patients. METHODS: We performed a cross-sectional study of 149 adult patients followed between 2000 and 2011 in a comprehensive sickle cell clinic. All patients were assessed for albuminuria either by direct measurement or by urinary chemical strip (dipstick) testing. Urinary albumin-to-creatinine ratios (UACRs) were available for 112 patients. Hydroxyurea exposure was defined as ≥3 months of therapy before the assessment of albuminuria. Albuminuria was defined as either UACR ≥30 mg/g or ≥1+ proteinuria on two separate dipsticks. We constructed a multivariate logistic regression model to assess the association between hydroxyurea and albuminuria. RESULTS: The prevalence of albuminuria was lower among patients on hydroxyurea (34.7 versus 55.4%; P = 0.01) as was median albumin excretion (17.9 versus 40.5 mg/g; P = 0.04). In multivariate analysis, hydroxyurea was associated with a lower likelihood of albuminuria (odds ratio 0.28, 95% CI: 0.11-0.75, P = 0.01), adjusting for age, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use, tricuspid regurgitant jet velocity, hypertension and acute chest syndrome. CONCLUSIONS: In our population of sickle cell patients, those using hydroxyurea were less than one-third as likely to exhibit albuminuria. Hydroxyurea use may prevent development of overt nephropathy or the progression of sickle cell disease nephropathy to end-stage renal disease, and its use for this indication merits further investigation.
BACKGROUND:Albuminuria is an early manifestation of sickle cell nephropathy. Prior small case series suggests benefit of hydroxyurea in reducing albuminuria, with a similar trend noted in pediatric studies. We aimed to comprehensively evaluate hydroxyurea use and prevalence of albuminuria in adult sickle cell patients. METHODS: We performed a cross-sectional study of 149 adult patients followed between 2000 and 2011 in a comprehensive sickle cell clinic. All patients were assessed for albuminuria either by direct measurement or by urinary chemical strip (dipstick) testing. Urinary albumin-to-creatinine ratios (UACRs) were available for 112 patients. Hydroxyurea exposure was defined as ≥3 months of therapy before the assessment of albuminuria. Albuminuria was defined as either UACR ≥30 mg/g or ≥1+ proteinuria on two separate dipsticks. We constructed a multivariate logistic regression model to assess the association between hydroxyurea and albuminuria. RESULTS: The prevalence of albuminuria was lower among patients on hydroxyurea (34.7 versus 55.4%; P = 0.01) as was median albumin excretion (17.9 versus 40.5 mg/g; P = 0.04). In multivariate analysis, hydroxyurea was associated with a lower likelihood of albuminuria (odds ratio 0.28, 95% CI: 0.11-0.75, P = 0.01), adjusting for age, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use, tricuspid regurgitant jet velocity, hypertension and acute chest syndrome. CONCLUSIONS: In our population of sickle cell patients, those using hydroxyurea were less than one-third as likely to exhibit albuminuria. Hydroxyurea use may prevent development of overt nephropathy or the progression of sickle cell disease nephropathy to end-stage renal disease, and its use for this indication merits further investigation.
Authors: Martin H Steinberg; Franca Barton; Oswaldo Castro; Charles H Pegelow; Samir K Ballas; Abdullah Kutlar; Eugene Orringer; Rita Bellevue; Nancy Olivieri; James Eckman; Mala Varma; Gloria Ramirez; Brian Adler; Wally Smith; Timothy Carlos; Kenneth Ataga; Laura DeCastro; Carolyn Bigelow; Yogen Saunthararajah; Margaret Telfer; Elliott Vichinsky; Susan Claster; Susan Shurin; Kenneth Bridges; Myron Waclawiw; Duane Bonds; Michael Terrin Journal: JAMA Date: 2003-04-02 Impact factor: 56.272
Authors: Allison E Ashley-Koch; Emmanuel C Okocha; Melanie E Garrett; Karen Soldano; Laura M De Castro; Jude C Jonassaint; Eugene P Orringer; James R Eckman; Marilyn J Telen Journal: Br J Haematol Date: 2011-09-13 Impact factor: 6.998
Authors: Ofelia Alvarez; Scott T Miller; Winfred C Wang; Zhaoyu Luo; M Beth McCarville; George J Schwartz; Bruce Thompson; Thomas Howard; Rathi V Iyer; Sohail R Rana; Zora R Rogers; Sharada A Sarnaik; Courtney D Thornburg; Russell E Ware Journal: Pediatr Blood Cancer Date: 2012-01-31 Impact factor: 3.167
Authors: Banu Aygun; Nicole A Mortier; Matthew P Smeltzer; Barry L Shulkin; Jane S Hankins; Russell E Ware Journal: Am J Hematol Date: 2012-12-17 Impact factor: 10.047
Authors: Penelope P Howards; Enrique F Schisterman; Charles Poole; Jay S Kaufman; Clarice R Weinberg Journal: Am J Epidemiol Date: 2012-08-17 Impact factor: 4.897
Authors: Rima S Zahr; Marianne E Yee; Jack Weaver; Katherine Twombley; Raed Bou Matar; Diego Aviles; Rajasree Sreedharan; Michelle N Rheault; Rossana Malatesta-Muncher; Hillarey Stone; Tarak Srivastava; Gaurav Kapur; Poornima Baddi; Oded Volovelsky; Jonathan Pelletier; Rasheed Gbadegesin; Wacharee Seeherunvong; Hiren P Patel; Larry A Greenbaum Journal: Pediatr Nephrol Date: 2019-04-03 Impact factor: 3.714
Authors: Omar Niss; Adam Lane; Monika R Asnani; Marianne E Yee; Ashok Raj; Susan Creary; Courtney Fitzhugh; Prasad Bodas; Santosh L Saraf; Sharada Sarnaik; Prasad Devarajan; Punam Malik Journal: Blood Adv Date: 2020-04-14